Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2025. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at 1:50 pm ET and conduct investor meetings throughout the day.
The presentation will be accessible via webcast at the scheduled time and will subsequently be available in the Investors section of the company's website.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was -2.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:50 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 1:50 pm ET on Tuesday, March 4, 2025 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.